Index Entries

Peter Doshi (senior editor), Fiona Godlee (former editor in chief), and Kamran Abbasi (editor in chief)
January 19, 2022
British Medical Journal

“Today, despite the global rollout of covid-19 vaccines and treatments, the anonymised participant level data underlying the trials for these new products remain inaccessible to doctors, researchers, and the public—and are likely to remain that way for years to come. This is morally indefensible for all trials, but especially for those involving major public health interventions…
  
The lack of access to data is consistent across vaccine manufacturers…
 
Pharmaceutical companies are reaping vast profits without adequate independent scrutiny of their scientific claims. The purpose of regulators is not to dance to the tune of rich global corporations and enrich them further; it is to protect the health of their populations. We need complete data transparency for all studies, we need it in the public interest, and we need it now.

document
COVID-19,FDA approvals,manufacturers,clinical trials,vaccines